Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
Clinical Multimodal Early Warning Surveillance of Respiratory Syndrome Pathogens and Construction and Application of Prevention and Control Measures
1 other identifier
observational
2,398
1 country
31
Brief Summary
This nationwide, multicenter observational study will establish and improve a hospital-based clinical surveillance and early warning system for respiratory syndrome pathogens. Clinical data and biospecimens generated during routine care will be collected from participating medical institutions every two weeks to monitor pathogen trends, support risk assessment, and provide evidence for prevention and control measures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2025
Typical duration for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2025
CompletedFirst Submitted
Initial submission to the registry
July 3, 2026
CompletedFirst Posted
Study publicly available on registry
July 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2028
July 10, 2026
July 1, 2026
3 years
July 3, 2026
July 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Detection rate and pathogen spectrum of respiratory syndrome pathogens among enrolled participants
3 years
Immune response and antibody levels after respiratory syndrome-related infection or vaccination
3 years
Study Arms (1)
Respiratory syndrome cohort
Patients entering fever clinics, emergency departments, outpatient clinics, or inpatient wards who meet the respiratory syndrome screening and diagnostic criteria.
Interventions
Participants will undergo clinically indicated tiered testing, including SARS-CoV-2 nucleic acid testing, influenza A/B antigen or nucleic acid testing, routine blood testing, targeted sequencing or multiplex PCR, metagenomic next-generation sequencing, respiratory pathogen antibody testing, cytokine testing, and exploratory transcriptomics, metabolomics, proteomics, single-cell, microbiome, and related analyses using collected or clinically remaining samples.
Eligibility Criteria
Patients with respiratory syndrome treated in fever clinics, emergency departments, outpatient clinics, or inpatient wards of participating medical institutions across China.
You may qualify if:
- Patients with respiratory syndrome: Eligible patients are those diagnosed with respiratory syndrome based on the predefined data dictionary and the following ICD-10 (International Statistical Classification of Diseases, 10th Revision) diagnosis codes: R05, R50, J00, J01, J02, J03, J04, J06, J07, J08, J09, J10, J11, J12, J13, J14, J15, J16, J17, J18, J20, J21, J98.414, and J98.802.
- Patients with respiratory syndrome: Eligible patients are identified using the following search criteria. Patients meeting any one of the following criteria should be included:
- Medical history (History of Present Illness): Positive test result for a respiratory syndrome-related pathogen.
- Laboratory testing: Positive test result for a respiratory syndrome-related pathogen.
- Medication: Receipt of any of the following antiviral agents:
- Nirmatrelvir/Ritonavir Leritrelvir Xiannuotewei/Ritonavir Molnupiravir Azvudine Deuremidevir
- Diagnosis: Diagnosis containing the term "respiratory tract infection."
You may not qualify if:
- Participants who may compromise the study results: Patients who are unable to provide a specimen or whose specimen volume is insufficient for laboratory testing.
- Participants who are unable to comply with study procedures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Huashan Hospitallead
Study Sites (31)
Beijing You'an Hospital, Capital Medical University
Beijing, Beijing Municipality, 100069, China
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510700, China
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, 519000, China
The 980th Hospital of the People's Liberation Army Joint Logistics Support Force
Shijiazhuang, Hebei, 050082, China
Heilongjiang Provincial Hospital
Harbin, Heilongjiang, 150036, China
Jiamusi Central Hospital
Jiamusi, Heilongjiang, 154002, China
Shangqiu Municipal Hospital
Shangqiu, Henan, 476000, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
Yichang Third People's Hospital
Yichang, Hubei, 443003, China
Hunan University of Medicine General Hospital
Huaihua, Hunan, 418000, China
The Third Hospital of Baotou (Baotou City Hospital for Infectious Diseases)
Baotou, Inner Mongolia, 014040, China
Nanjing Hospital of Chinese Medicine
Nanjing, Jiangsu, 210022, China
The Third People's Hospital of Nantong (Nantong Hospital of Infectious Diseases)
Nantong, Jiangsu, 226006, China
Wuxi Fifth People's Hospital
Wuxi, Jiangsu, 214005, China
Jiujiang No.1 People's Hospital
Jiujiang, Jiangxi, 332000, China
Shenyang Sixth People's Hospital
Shenyang, Liaoning, 110006, China
Affiliated Hospital of Yan'an University
Yan’an, Shaanxi, 716000, China
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, 277100, China
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, 200040, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
Jinyang Community Health Service Center of Pudong New Area, Shanghai
Shanghai, Shanghai Municipality, 200136, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center
Shanghai, Shanghai Municipality, 201399, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001, China
Children's Hospital of Shanxi Province
Taiyuan, Shanxi, 030013, China
Characteristic Medical Center of Chinese People's Armed Police Force
Tianjin, Tianjin Municipality, 300162, China
Altay Prefecture People's Hospital, Xinjiang
Altay, Xinjiang, 836500, China
Changji Hui Autonomous Prefecture People's Hospital
Changji, Xinjiang, 831100, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830054, China
Hekou Yao Autonomous County People's Hospital
Hekou, Yunnan, 661399, China
The First People's Hospital of Yunnan Province
Kunming, Yunnan, 650032, China
Biospecimen
Nasopharyngeal and/or oropharyngeal swabs, sputum, clinically remaining bronchoalveolar lavage fluid, stool, urine, peripheral blood, and other clinically remaining samples when applicable will be used for pathogen detection, sequencing, antibody testing, cytokine testing, and exploratory multi-omics analyses.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
July 3, 2026
First Posted
July 10, 2026
Study Start
September 1, 2025
Primary Completion (Estimated)
August 31, 2028
Study Completion (Estimated)
September 30, 2028
Last Updated
July 10, 2026
Record last verified: 2026-07